Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 27 Apr 2016 |
| Decision by the Board of Directors to acquire own shares | 27 Apr 2016 |
| Publishing of Orion Corporation's Interim Report for January-March 2016 on 27 April 2016 | 13 Apr 2016 |
| 125,000 Orion Corporation A shares converted into B shares | 12 Apr 2016 |
| Orion Corporation: Organising meeting of the Board of Directors | 22 Mar 2016 |